At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 133 enrolled
Drug / intervention
Camidanlumab tesirinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Adaptive Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-301 in Patients With Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma
In Brief
A Phase 1 clinical trial evaluating Camidanlumab tesirine for Hodgkin Lymphoma and Non-Hodgkin Lymphoma. Completed, enrolled 133 participants across 12 sites in 2 countries.
Detailed Summary
This study evaluates camidanlumab tesirine in participants with relapsed/refractory Non-Hodgkin or Hodgkin lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHodgkin Lymphoma, Non-Hodgkin Lymphoma
CountriesUnited Kingdom, United States
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartOct 2015
Primary CompletionOct 2019
TodayJul 2026
First PostedMay 4, 2015
Enrollment StartOct 5, 2015
Primary CompletionOct 24, 2019
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 11.2 years ago
Interventions
Camidanlumab tesirinedrug
Intravenous (IV) infusion.